SAN DIEGO and SUZHOU, China and SPRING HOUSE, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG) ...

Third Arc Bio is paying $5 million upfront to use Adagene’s tech in hopes of creating two new masked T-cell engagers. | Third ...

"Solid tumors are often difficult to treat because the immune system within the tumor gets switched off," said Michelle H. Nelson, PhD, Director of Immunobiology at Aptevo. "APVO451 is designed to ...

Poster presentation outlines potential of CD3 Switch-DARPin T cell engager (TCE) using an AND-gate to overcome limitations of other TCEsDemonstrated selective T cell cytotoxicity against cells ...

Exploratory Phase 2 analysis shows Verrica’s novel oncolytic peptide, VP-315, reprograms the tumor microenvironment, ...

HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing ...

Presented new preclinical data on INB-619, a novel gamma-delta (γδ) T cell engager (TCE), demonstrating equivalent potency ...

Novel INDUCER™ T Cell Engager Platform designed to mitigate systemic toxicities Sequential dosing of INDUKINE™ molecules in ...

Sino-American antibody company Adagene and Third Arc Bio today announced a licensing agreement under which Third Arc Bio will ...

Urolithin A, a natural postbiotic known to trigger mitophagy, rejuvenated key immune cell functions in healthy middle-aged ...

Early immune activation marks the onset of rheumatoid arthritis, revealing potential for early intervention and improved ...

Dr. Simon Plyte, Biomunex's CSO, has been invited to present MAIT engagers preclinical data during an oral communication at 2025 SITC Annual meeting -- With a very attractive safety and efficacy ...